Vireo Growth Aktie Logo
CA92767B1058
A40GZV
0ZF.MU

Vireo Growth Aktie

Loading quotes...

Forecast

The analysts' average price target is €0.39 (-95.49%). The median is €0.39 (-95.49%).

Buy
  0
Hold
  2
Sell
  0

  • Vireo Growth acquires C21 Investments, expands Nevada presence

    Vireo Growth has completed the acquisition of C21 Investments through a court‑approved arrangement proceeding and issued 2,766,409 Vireo shares in connection with the deal. C21 shareholders received 0.023052 subordinate voting Vireo shares for each common share; C21’s shares are to be delisted from the CSE and OTCQX trading will be discontinued. The acquisition gives Vireo three additional retail locations in Nevada and roughly 104,000 square feet of cultivation and production capacity, bringing its Nevada footprint to about 14 retail locations and 159,000 square feet of capacity. » More on de.investing.com


  • Vireo Growth acquires PhytoNatural and secures Pennsylvania license for up to six dispensaries

    Vireo Growth has completed the acquisition of PhytoNatural, thereby obtaining a previously unused license to distribute medical cannabis in Pennsylvania. The transaction was carried out through the joint venture Vive Penn with Hive Holdings and has a total value of $20.0 million, consisting of $8.0 million in cash and roughly $12.0 million in approximately 645,161 subordinated voting shares to be issued in two years. The license permits, subject to regulatory approvals, the operation of up to six dispensing locations; Vireo already operates more than 170 dispensaries across ten U.S. states. » More on de.investing.com


  • Vireo Growth completes acquisition of Bridgewell for $13.66 million

    Vireo Growth has completed the acquisition of Agribusiness Holdings Limited Partnership, including Bridgewell; the final purchase price for the Bridgewell transaction is approximately $13.66 million. As consideration, the sellers were issued unsecured, subordinated convertible notes that are convertible, at the earliest in two years, into an estimated 22,036,528 subordinated voting shares at an assumed price of $0.62 per share (pre-consolidation). Vireo cites strong revenue growth (251% to $350.47 million) and also reports the purchase of the M3 Wellness dispensary in Nevada for $500,000 as well as a previously agreed 49% stake in two Maryland companies for $1.55 million, both transactions subject to regulatory approvals. » More on de.investing.com

Financials

In the last quarter, Vireo Growth Aktie had revenue of €183.39M and net profit of -€85.4K
(EUR) Jun 2026
YoY
Revenue 183.39M 349.73%
Gross profit 83.5M 382.04%
Net profit -85.4K 99.33%
EBITDA 16.65M 4,261.36%

Fundamentals

Metric Value
Market capitalization
€349.88M
Number of shares
38.25M
52-week high/low
€19.41 - €7.69
Dividends No
Beta
0.07
P/E ratio
-5.37
PEG ratio
-0.08
P/B ratio
1.08
P/S ratio
0.79

Company profile

Name
Vireo Growth Aktie
CEO
John Mazarakis
Employees 612

Ticker symbols

Exchange Symbol
München
0ZF.MU
🍪

Parqet  uses cookies. Learn more